Mobile system tracks assets

TAKE Supply Chain, formerly ClearOrbit, has unveiled an Internet-based mobile application that automates asset data collection for the tracking and reporting of fixed assets, both capital and physical. The Asset Tracking and Maintenance Solution combines handheld barcode tag printing, RFID scanner technology and a link to the company's existing data system, according to an announcement. Handheld devices permit asset tracking by location, item ID or serial number, feeding inventory and maintenance data to the ERP for a consolidated view of asset status, location and activity.

Additional functionality aids in the planning and scheduling of repair and maintenance, as well as the tracking of associated expenses. The system streamlines a traditionally manually intensive process, the company says.

Separately, TAKE announced last month that global specialty drugmaker Three Rivers Pharmaceuticals had achieved a 50% increase in distribution efficiency and productivity by implementing the Gemini Simplified Interface for Oracle Process Manufacturing to automate warehouse transactions, provide inventory visibility and enable track/trace capabilities across its supply chain. Three Rivers used the Gemini system's mobile radio-frequency scanners for visibility of inbound materials and products throughout its distribution facility. It also used Gemini's compliance label manager to automate labeling and produce barcode labels and RFID tags.

The real-time supply chain execution company formally changed its name from ClearOrbit to TAKE Supply Chain to highlight its transition to a division under parent company TAKE Solutions, which acquired ClearOrbit in 2007.

-read the asset tracking announcement
-read the Three Rivers release

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.